WATERTOWN, Mass. (AP) — WATERTOWN, Mass. (AP) — EyePoint Pharmaceuticals (EYPT) on Thursday reported a loss of $29.4 million in its third quarter.
On a per-share basis, the Watertown, Massachusetts-based company said it had a loss of 54 cents.
The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 48 cents per share.
The drug delivery technology company posted revenue of $10.5 million in the period, also missing Street forecasts. Three analysts surveyed by Zacks expected $12.4 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on EYPT at https://www.zacks.com/ap/EYPT
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。